Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03251924
Title A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP | CHE | CAN


No variant requirements are available.